Abstracts tagged "Immunotherapy"

Abstract Number: 2139 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune-Related Adverse Events Associated with Treatment with Immune Checkpoint Inhibitors: A Multicenter Study of 38 Cases
Sebastian Rodriguez-Garcia¹, David Lobo ², Fabiola Ojeda ³, Raul Castellanos-Moreira ⁴, Ana Laiz ², Roberto Gumucio ⁴, Cesar Diaz-Torné ², Virginia Ruiz-Esquide ⁵, Milena Millan ², Ivan Castellvi ⁶, Patricia Moya Alvarado ⁷, Berta Magallares ², Carolina Perez ³, Hector Corominas ⁸ and Jose Gomez-Puerta ⁹, ¹Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Spain, ²Rheumatology Department. Hospital Sant Pau, Barcelona, Catalonia, Spain, ³Rheumatology Department. Hospital del Mar, Barcelona, Catalonia, Spain, ⁴Rheumatology Department. Hospital Clínic Barcelona, Barcelona, Catalonia, Spain, ⁵Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Catalonia, Spain, ⁶Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, Catalonia, Spain, ⁸Rheumatology Department, Hospital Sant Pau, Barcelona, Catalonia, Spain, ⁹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain
Background/Purpose: Immune checkpoint inhibitors (ICI) against CTLA-4 or PD- 1/PD-L1 and more recently TIM3, have demonstrated efficacy in improving the survival of patients with diverse…
Abstract Number: 2140 • 2019 ACR/ARP Annual Meeting
Preexisting Autoimmune Disease and Rheumatic Immune-Related Adverse Events Associated with Cancer Immunotherapy: A Case Series from the Canadian Research Group of Rheumatology in Immuno-Oncology (CanRIO)
Linda Laaouad¹, Janet Roberts ², Daniel Ennis ³, Carrie Ye ⁴, Karam Al Jumaily ⁵, Marie Hudson ⁶, Shahin Jamal ⁷, Janet Pope ⁸, Tatiana Nevskaya ⁹, Alexandra Saltman ¹⁰, Megan Himmel ¹¹, Aurore Fifi-Mah ¹², Annaliese Tisseverasinghe ¹³, Nancy Maltez ¹⁴, Ines Colmegna ¹⁵ and Sabrina Hoa ¹⁶, ¹University of Montreal, Montreal, Canada, ²Dalhousie University, Halifax, Canada, ³University of Toronto, Toronto, ON, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Alberta, Edmonton, Canada, ⁶Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁷University of British Columbia, Vancouver, BC, Canada, ⁸Western University, London, ON, Canada, ⁹University of Western Ontario, London, ON, Canada, ¹⁰University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Calgary, Calgary, AB, Canada, ¹³University of Manitoba, Winnipeg, MB, Canada, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵McGill University Health Center, Montreal, QC, Canada, ¹⁶University of Montreal, Montreal, QC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the immune system to fight cancer, but are associated with significant immune-related adverse events…
Abstract Number: 2146 • 2019 ACR/ARP Annual Meeting
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Emily Carroll¹, Amanda Leiter ², Danielle Brooks ¹, Jennifer Ben Shimol ³, Elliot Eisenberg ¹, Matthew Galsky ⁴, Emily Gallagher ⁵ and Margrit Wiesendanger ³, ¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ²Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, ⁵Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs).…
Abstract Number: 2147 • 2019 ACR/ARP Annual Meeting
Musculoskeletal Ultrasound Enhances the Evaluation of Checkpoint Inhibitor Associated Musculoskeletal Immune Related Adverse Events
Mazen Nasrallah¹, Sara Schoenfeld ², Mark Matza ¹, Donald Lawrence ², Justine Cohen ², Meghan Mooradian ², Kerry Reynolds ², Ryan Sullivan ² and Minna Kohler ², ¹Massachusetts General Hospital, Boston, ²MGH, Boston
Background/Purpose: Cancer immunotherapy with monoclonal antibodies that antagonize molecular checkpoint pathways in immune activation, the PD-1/PDL1 axis and CTLA-4, have revolutionized the treatment of solid…
Abstract Number: 2157 • 2019 ACR/ARP Annual Meeting
Checkpoint Inhibitor-Associated Arthritis: Phenotype, Steroid Dose, Serology and Survival
Karmela Kim Chan ¹, Aidan Tirpack ¹, Caroline Benson ¹, Gregory Vitone ¹, Jackie Finik ², Vivian Bykerk ³, Susan Goodman ⁴, Laura Donlin ⁵, Deepak Rao ⁶ and Anne Bass⁴, ¹Hospital For Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, New York, NY, ³Hospital for Special Surgery, New York City, NY, ⁴Hospital For Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital For Special Surgery, New York, NY, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Previous studies suggest that steroid dose1and rheumatoid factor positivity2 impact cancer survival in checkpoint inhibitor (CI)-treated patients (with CI-associated hypophysitis, and in all-comers with non-small…
Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Janet Roberts¹, Daniel Ennis ², Marie Hudson ³, Carrie Ye ⁴, Alexandra Saltman ⁵, Sabrina Hoa ⁶, Janet Pope ⁷, Megan Himmel ², Nancy Maltez ⁸, Aurore Fifi-Mah ⁹, Annaliese Tisseverasinghe ¹⁰, Robert Rottapel ¹¹, Karam Al Jumaily ¹², Christina Ly ¹³, Liliana Cartagena ¹⁴ and Shahin Jamal ¹⁵, ¹Dalhousie University, Halifax, NS, Canada, ²University of Toronto, Toronto, ON, Canada, ³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Western University, London, ON, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Alberta, edmonton, Canada, ¹³McGill University, Montreal, Canada, ¹⁴Arthritis Research Canada, Vancouver, Canada, ¹⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer. They are associated with the development of autoimmune…
Abstract Number: 84 • 2019 ACR/ARP Annual Meeting
Cenerimod, a Potent and Selective Sphingosine-1-Phosphate Receptor 1 Modulator, Controls Systemic Autoimmunity and Organ Pathology in Mouse Models of Systemic Lupus Erythematosus and Sjögren’s Syndrome
Estelle Gerossier ¹, Saba Nayar ², Charlotte Smith ², Sylvie Froidevaux ³, Francesca Barone ² and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Basel-Landschaft, Switzerland, ²Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom, ³Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland
Background/Purpose: Autoimmune diseases including SLE and SS are characterized by aberrant lymphocyte activation and autoantibody production. This results in systemic manifestations and the formation of…
Abstract Number: 253 • 2019 ACR/ARP Annual Meeting
A Systematic Review and Meta-analysis of Observational Studies Reporting on the Use of Checkpoint Inhibitors in Patients with Cancer and Pre-existing Autoimmune Disease
Maria Lopez-Olivo¹, Noha Abdel-Wahab ¹ and Maria E. Suárez-Almazor ², ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX
Background/Purpose: Immune checkpoint inhibitors (ICI) are increasingly used in the treatment of cancer. To date, no clinical trials exist evaluating the use of ICI in…
Abstract Number: 1339 • 2019 ACR/ARP Annual Meeting
Risk of Immunotherapy Related Toxicity in Patients with Rheumatoid Arthritis
Elizaveta Efuni ¹, Samuel Cytryn ², Patrick Boland ² and Sabina Sandigursky³, ¹New York University School of Medicine, New York, NY, ²NYU Langone Health, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) have changed the therapeutic landscape in oncology leading to cures in some cancer types. However, patients with pre-existing autoimmune diseases…
Abstract Number: 1808 • 2019 ACR/ARP Annual Meeting
Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation
Tawnie Braaten¹, Julie Brahmer ¹, Patrick Forde ¹, Dung Le ¹, Evan Lipson ¹, Jarushka Naidoo ¹, Megan Schollenberger ¹, Lei Zheng ¹, Michelle Jones ¹, Ami Shah ², Clifton Bingham ³ and Laura Cappelli ³, ¹Johns Hopkins, Baltimore, MD, ²Johns Hopkins Hospital, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD
Background/Purpose: The use of immune checkpoint inhibitor (ICI) therapy for malignancy is growing. Various autoimmune and inflammatory syndromes, known as immune-related adverse events (irAEs) have…
Abstract Number: 1956 • 2019 ACR/ARP Annual Meeting
Characterizing Arthritis Related to Immune Checkpoint Inhibitors Using Synovial Fluid and Matched Blood
Mazen Nasrallah¹, Molly Thomas ², Kasidet Manakongtreecheep ², Daniel Zlotoff ², Aleigha Lawless ², Hellen Giang ², Sara Schoenfeld ², Ryan Sullivan ², Genevieve Boland ², Kerry Reynolds ², Minna Kohler ², Andrew Luster ² and Alexandra-Chloé Villani ², ¹Massachusetts General Hospital, Boston, ²MGH, Boston
Background/Purpose: Monoclonal antibodies against CTLA-4 and PD-1 have revolutionized the field of immuno-oncology over the past decade. These therapies however are limited by immune related…
Abstract Number: 2137 • 2019 ACR/ARP Annual Meeting
Overall Survival in Patients with PD-1 Inhibitor-related Inflammatory Arthritis and Metastatic Melanoma
Michael Richter¹, Jacob Orme ², Heidi Finnes ³ and Uma Thanarajasingam ⁴, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Hematology and Oncology, Mayo Clinic, Rochester, MN, ³Department of Pharmacy, Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: The development of de novo inflammatory arthritis (IA) occurs in 2-4% of all patients with cancer treated with programmed cell death protein 1 (PD-1)…
Abstract Number: 358 • 2018 ACR/ARHP Annual Meeting
Immunophenotypic Analysis of T Cells from Leukemia Patients with Immune Checkpoint Inhibitor-Associated Respiratory Complications
Sang Kim¹, Vickie Shannon², Ajay Sheshardi², Hagop Kantarjian³, Guillermo Garcia-Manero³, Farhad Ravandi³, Aung Naing⁴, Padmanee Sharma⁵, Jin Im⁶, Wilfredo Ruiz Vazquez⁶, Adi Diab⁷, Dimitrios Kontoyiannis⁸, Andrew Futreal⁹ and Naval Daver³, ¹General Internal Medicine, MD Anderson Cancer Center, Houston, TX, ²Pulmonary Medicine, MD Anderson Cancer Center, Houston, TX, ³Leukemia, MD Anderson Cancer Center, Houston, TX, ⁴Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, ⁵Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, TX, ⁶Stem Cell Transplantation, MD Anderson Cancer Center, Houston, TX, ⁷Melanoma Medical Oncology, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁸Infectious Diseases, MD Anderson Cancer Center, Houston, TX, ⁹Genomic Medicine, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Immune checkpoint inhibitor (ICI)-based combinations are showing encouraging results in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) treatment; however, ICIs can cause immune-related…
Abstract Number: 360 • 2018 ACR/ARHP Annual Meeting
Sarcoidosis Induced By Immune Check Point Inhibitors
Noémie Chanson¹, Pauline Pradère², Anne-Laure Voisin³, Stéphane Champiat⁴, Aurélien Marabelle⁴ and Olivier Lambotte⁵, ¹Internal Medicine, Hopital Bicetre, LE KREMLIN BICETRE, France, ²Hopital Marie Lannelongue, Le Plessis Robinson, France, ³Unité Fonctionnelle de Pharmacovigilance, Gustave Roussy Institut, Villejuif, France, ⁴Drug Development Department, Gustave Roussy Institut, Villejuif, France, ⁵Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France
Background/Purpose: Immune check point inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) have demonstrated improved survival for multiple cancers…
Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
In Young Kim¹, Yeonghee Eun¹, Hyungjin Kim¹, Joong Kyong Ahn², Eun-Jung Park³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hoon-Suk Cha¹, Eun-Mi Koh¹ and Jaejoon Lee¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].